IPO Timeline
Broker Results (T-2)
2021-02-04
Some brokers release in afternoon
Grey Market (T-1)
2021-02-05
Afternoon
HKEX Allotment (T-1)
2021-02-05
Evening
Registrar Allotment (T-1)
2021-02-05
Evening
Listing Day (T)
2021-02-08
First day of trading
Company Overview
| Stock Name | 蘇州貝康醫療股份有限公司 - B - H股 |
|---|---|
| Stock Code | 02170 |
| Company Full Name | 蘇州貝康醫療股份有限公司 - B - H股 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事輔助生殖基因檢測解決方案，包括提供基因檢測試劑盒、基因檢測設備及儀器，以及相關服務。 |
| Listing Date | 2021-02-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園A3樓101室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.basecare.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 27.36 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 38.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 912,045,600 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 27.7 |
|---|---|
| First Day Open | HK$ 30.0 |
| First Day Change | 1.24% |
| First Day Volume | 50895400.0 |
| First Day Turnover | 1543960000.0 |
Use of Proceeds
| Use of Proceeds | 1、約30%或515.0百萬港元將分配予我們的核心產品PGT-A試劑盒； 2、約20%或343.3百萬港元將用于PGT-M試劑盒的臨床試驗、注冊申報及商業化； 3、約30%或515.0百萬港元將分配用于我們其他產品的開發、臨床試驗及注冊申報； 4、約10%或171.7百萬港元將用于提高我們的研發能力及提升我們的技術； 5、約10%或171.7百萬港元將用作我們的營運資本及一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中信证券（香港）有限公司 CE AAK249
Overall Coordinators (3)
中信里昂证券有限公司 CE AAB893
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (7)
中信里昂证券有限公司 CE AAB893
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
招银国际融资有限公司 CE AVM940
工银国际证券有限公司 CE ARO299
浦银国际融资有限公司 CE BFZ375
Joint Lead Managers (8)
中信里昂证券有限公司 CE AAB893
花旗环球金融亚洲有限公司 CE AAA137
中国国际金融香港证券有限公司 CE AEN894
海通国际证券有限公司 CE AAF806
招银国际融资有限公司 CE AVM940
工银国际证券有限公司 CE ARO299
浦银国际融资有限公司 CE BFZ375
富途证券国际（香港）有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Affin Hwang Asset Management Berhad | 77,524,560 HKD | — | 4.30% | — | 6 months | 2021-08-08 |
| 2 | CRF Investment Holdings Company Limited | 155,062,800 HKD | — | 8.50% | — | 6 months | 2021-08-08 |
| 3 | Foresight Orient Global Superior Choice SPC | 38,755,440 HKD | — | 2.10% | — | 6 months | 2021-08-08 |
| 4 | Lake Bleu Prime Healthcare Master Fund Limited | 155,062,800 HKD | — | 8.50% | — | 6 months | 2021-08-08 |
| 5 | OrbiMed Funds | 155,062,800 HKD | — | 8.50% | — | 6 months | 2021-08-08 |
| 6 | WinTwin Capital Limited | 77,524,560 HKD | — | 4.30% | — | 6 months | 2021-08-08 |
| 7 | 常春藤资产管理(香港)有限公司 | 38,755,440 HKD | — | 2.10% | — | 6 months | 2021-08-08 |
Directors & Management
| Chairman | 梁波 |
|---|---|
| Company Secretary | 殷樂駿,溫詠宜 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 梁波(33.38%);徐文博(8.11%);北京中誠方圓二期投資中心(有限合伙)(5.55%) |
|---|
IPO Timeline
